Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | USP5 | P45974 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150034 | 0.91 | KMT2A (0.53) | KMT2AKDM4EALDH1A1POLBHTT | |
| SCHEMBL18258624 | 0.91 | KMT2A (0.53) | KMT2AKDM4EALDH1A1POLBHTT | |
| SCHEMBL21027022 | 0.82 | SYK (0.39) | P2RX4GLAKMT2AKDM4EPOLB | |
| SCHEMBL21027528 | 0.82 | SYK (0.39) | P2RX4GLAKMT2AKDM4EPOLB | |
| SCHEMBL21027516 | 0.82 | SYK (0.39) | P2RX4GLAKMT2AKDM4EPOLB | |
| SCHEMBL8602904 | 0.81 | P2RX4 (0.53) | P2RX4GLAKDM4EALDH1A1POLB | |
| SCHEMBL18180382 | 0.79 | KMT2A (0.45) | KMT2AKDM4EPOLBHTTUSP5 | |
| SCHEMBL21027990 | 0.79 | NTRK1 (0.50) | P2RX4GLAKMT2AKDM4EALDH1A1 | |
| SCHEMBL16468650 | 0.79 | KMT2A (0.43) | KMT2AKDM4EALDH1A1POLBHTT | |
| SCHEMBL11826429 | 0.79 | KDM4E (0.51) | KMT2AKDM4EALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002230-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10745358-B2 | Oxoacridinyl acetic acid derivatives and methods of use | SILICON SWAT, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190161449-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | SILICON SWAT, INC. | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161449-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | STING1, IRF3, CGAS | P2RX4 2813/4885GLA 364/4885KMT2A 4787/4885 |
| US-20210002230-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | STING1, IRF3, CGAS | P2RX4 2813/4885GLA 364/4885KMT2A 4787/4885 |
| US-10745358-B2 | Oxoacridinyl acetic acid derivatives and methods of use | STING1, IRF3, CGAS | P2RX4 2813/4885GLA 364/4885KMT2A 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.